香莱克:一种用于缓解炎症性肠病的新型免疫调节策略
Radmila Miljkovic1, Emilija Marinkovic1, Ivana Lukic1
1Department of Research and Development, Institute of Immunology, Virology, Vaccines and Sera-Torlak, 11152 Belgrade, Serbia.
Nutrients
|June 19, 2024
概括
重组香莱克 (rBanLec) 在治疗炎症性肠病 (IBD) 和增强免疫反应方面表现有前途,可能改善接受免疫抑制治疗的IBD患者的疫苗接种率.
科学领域:
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 炎症性肠病 (IBD) 患者的疫苗接种率较低,增加了疫苗可预防疾病的风险.
- 用于IBD管理的免疫抑制疗法进一步损害了免疫功能和疫苗的疗效.
研究的目的:
- 为了研究重组香学菌素 (rBanLec) 在管理实验性结肠炎中的治疗潜力.
- 评估rBanLec调节免疫反应的能力,并可能改善IBD患者的疫苗接种结果.
主要方法:
- 在C57BL/6和BALB/c小鼠中使用2,4,6-三二二硫酸诱导实验性结肠炎.
- 在疾病进展过程中,小鼠接受了口服治疗,服用不同剂量的rBanLec.
- 评估了结肠炎的严重程度,免疫反应调节 (包括TNFα和IL-10水平) 和恢复.
主要成果:
- rBanLec的使用表明大肠炎严重程度的逆剂量反应减少,包括更少的体重减轻和结肠缩短.
- 在小鼠模型中,治疗导致了改善的恢复概况.
- rBanLec显著调节了免疫反应,有利于疫苗接种至关重要的抗炎途径.
结论:
- rBanLec在炎症性肠病 (IBD) 中表现出治疗潜力.
- rBanLec的免疫调节作用可能会抵消IBD疗法的免疫抑制,从而可能提高疫苗的响应能力.
- rBanLec可以为IBD患者提供双重好处:改善疾病控制和更好地预防疫苗可以预防的疾病.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Inflammatory Bowel Disease IV: Pharmacological Management
125
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
125
Drugs for Treatment of Ulcerative Colitis in IBD
135
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
135
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
156
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
156
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
130
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
130
Drugs for Treatment of Constipation-Predominant IBS
155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155


